The search for novel anticancer agents with more selectivity and lower toxicity continues to
be an area of intensive investigation. The unique structural features of spirooxindoles …

Design of small-molecule inhibitors (MDM2 inhibitors) to block the MDM2–p53 protein–
protein interaction has been pursued as a new cancer therapeutic strategy. In recent years …

Halogen bonding has been known in material science for decades, but until recently,
halogen bonds in protein–ligand interactions were largely the result of serendipitous …

Restoration of p53 activity by inhibition of the p53–MDM2 interaction has been considered
an attractive approach for cancer treatment. However, the hydrophobic protein–protein …

The emergence and convergence of cancer genomics, targeted therapies, and network
oncology have significantly expanded the landscape of protein–protein interaction (PPI) …

Protein-protein interaction (PPI) is a hot topic in clinical research as protein networking has a
major impact in human disease. Such PPIs are potential drugs targets, leading to the need …

Disruption of the MDM2-p53 protein-protein interaction by small-molecule inhibitors has
been highly pursued by many academic laboratories and pharmaceutical companies as a …

We recently reported the discovery of AM-8553 (1), a potent and selective piperidinone
inhibitor of the MDM2–p53 interaction. Continued research investigation of the N-alkyl …

Protein–protein interactions (PPIs) are key elements of several important biological
processes and have emerged as valuable targets in medicinal chemistry. Importantly …

Abstract Mouse double minute 2 (MDM2) is an E3 ubiquitin ligase which effectively
degrades tumor suppressor p53. In the past two decades, many MDM2 inhibitors that disrupt …